department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

National Cancer Institute US · pharmadog

PUBLIC COMPANY

National Cancer Institute US

updated 1mo ago

community read0 votes

pipeline

5

marketed

0

phase 3

0

catalysts ytd

10

approvals ytd

0

recalls ytd

0

Pipeline(5)

pipeline depth5 products

1Phase 14Unknown

Gene Therapy to Target CD22 for Oncology

B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphobla…

Autologous B7-H3 CAR T

undisclosed chemotherapy

Upcoming

no upcoming catalysts on record

Recent(90d)

phase 1 completion (3) · phase 1 2 initiation (2) · phase 2 completion (1) · phase 2 initiation (3) · phase 1 initiation (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view National Cancer Institute US jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

mentioned in

0news items

entity-linker matched

phase 1 completion

National Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)

emavusertib hydrochloride

phase 1 2 initiation

National Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)

phase 2 completion

National Cancer Institute US — ipilimumab (Phase II Trial Completion)

phase 1 completion

National Cancer Institute US — tuvusertib (Phase I Trial Completion)

phase 2 initiation

National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)

(daratumumab + hyaluronidase (human recombinant))

phase 1 completion

National Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)

undisclosed chemotherapy

phase 1 2 initiation

National Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)

sacituzumab govitecan

phase 2 initiation

National Cancer Institute US — busulfan (Phase II Trial Initiation)

phase 2 initiation

National Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)

cyclophosphamide

phase 1 initiation

National Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)

Autologous B7-H3 CAR T

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagOncology35 co-mentions · 10 sources
tagHepatology3 co-mentions · 1 sources
tagPulmonology2 co-mentions · 2 sources
tagMultiple Myeloma2 co-mentions · 1 sources
tagNSCLC2 co-mentions · 2 sources
tagGlioblastoma2 co-mentions · 1 sources
drugdaratumumab1 co-mentions · 1 sources
tagHematology1 co-mentions · 1 sources